SCHEMBL934486

SCHEMBL934486

[CH2]CCSCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 4/20 0.55
CYP1A2 P05177 3/20 0.53
CYP2D6 P10635 3/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2C9 P11712 2/20 0.53
ALDH1A1 P00352 4/20 0.46
HPGD P15428 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 1/20 0.46
ALPL P05186 1/20 0.44
ALPI P09923 1/20 0.44
ALPG P10696 1/20 0.44
HTT P42858 1/20 0.44
GBA1 P04062 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
IDO1 P14902 1/20 0.40
NOS3 P29474 1/20 0.40
NOS1 P29475 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8748290 0.92 CYP2C19 (0.48) CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9
SCHEMBL5979449 0.86 CYP2C19 (0.52) CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9
SCHEMBL3078147 0.85 CYP2C19 (0.64) CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9
SCHEMBL5272714 0.85 CYP2C19 (0.50) CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9
SCHEMBL539499 0.83 CYP2C19 (0.48) CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9
SCHEMBL5073228 0.83 CYP2C19 (0.48) CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9
SCHEMBL5975033 0.81 CYP1A2 (0.61) CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9
SCHEMBL6306047 0.80 CYP2C19 (0.59) CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9
SCHEMBL7909121 0.80 CYP2C19 (0.59) CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9
SCHEMBL291657 0.80 CYP2C19 (0.48) CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239922-A1 PHOTOCURABLE COMPOSITION TOKYO OHKA KOGYO CO., LTD. (JP) 2024-07-18 US disclosed
US-20240192593-A1 PHOTOSENSITIVE COMPOSITION TOKYO OHKA KOGYO CO., LTD. (JP) 2024-06-13 US disclosed
US-20240191003-A1 COMPOSITION AND PHOTOSENSITIVE COMPOSITION TOKYO OHKA KOGYO CO., LTD. (JP) 2024-06-13 US disclosed
CN-117999296-A Composition and photosensitive composition 东京应化工业株式会社 2024-05-07 CN disclosed
CN-117980347-A Photosensitive composition 东京应化工业株式会社 2024-05-03 CN disclosed
CN-117980346-A Composition and photosensitive composition 东京应化工业株式会社 2024-05-03 CN disclosed
US-20240141085-A1 PHOTOCURABLE LIQUID COMPOSITION, CURED PRODUCT, AND METHOD FOR PRODUCING CURED PRODUCT TOKYO OHKA KOGYO CO., LTD. (JP) 2024-05-02 US disclosed
CN-117908327-A Composition and photosensitive composition 东京应化工业株式会社 2024-04-19 CN disclosed
CN-117908326-A Photosensitive composition 东京应化工业株式会社 2024-04-19 CN disclosed
EP-4317196-A1 PHOTOCURABLE COMPOSITION TOKYO OHKA KOGYO CO., LTD. (JP) 2024-02-07 EP disclosed
EP-1060183-A1 5'-DEOXYCYTIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2000-12-20 EP disclosed
EP-1057831-A2 Process for the preparation of vinyl pyrimidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2000-12-06 EP disclosed
US-6005098-A 5'deoxycytidine derivatives HOFFMANN-LA ROCHE INC. (US) 1999-12-21 US disclosed
WO-1999040099-A1 5'-DEOXYCYTIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1999-08-12 WO disclosed
US-5929177-A LIVING POLYMER WITH HYDROPHILIC, HYDROPHOBIC SEGMENTS Kataoka, Kazunori (JP) 1999-07-27 US disclosed
CN-1206423-A Peptide derivatives of Dolastatin 15 and their use BASF AG (DE) 1999-01-27 CN disclosed
EP-0844269-A1 BLOCK POLYMER HAVING FUNCTIONAL GROUPS AT BOTH ENDS Kataoka, Kazunori (JP) 1998-05-27 EP disclosed
CN-1150419-A Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same RHONE POULENC RORER SA (FR) 1997-05-21 CN disclosed
US-4393070-A HYPOTENSIVE, VASODILATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-07-12 US disclosed
US-4307103-A TREATMENT OF HYPERTENSION AND CARDIOVASCULAR DISEASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240192593-A1 PHOTOSENSITIVE COMPOSITION PPOX, ERCC1, ERCC5 CYP2C19 2110/4885CYP1A2 3273/4885CYP2D6 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.